Partin Kathryn M
Department of Biomedical Sciences, Colorado State University, Fort Collins, Co 80523-1617, United States.
Curr Opin Pharmacol. 2015 Feb;20:46-53. doi: 10.1016/j.coph.2014.11.002. Epub 2014 Nov 27.
Positive allosteric modulators of ionotropic glutamate receptors have emerged as a target for treating cognitive impairment and neurodegeneration, but also mental illnesses such as major depressive disorder. The possibility of creating a new class of pharmaceutical agent to treat refractive mental health issues has compelled researchers to redouble their efforts to develop a safe, effective treatment for memory and cognition impairments. Coupled with the more robust research methodologies that have emerged, including more sophisticated high-throughput-screens, higher resolution structural biology techniques, and more focused assessment on pharmacokinetics, the development of positive modulators of AMPA receptors holds great promise. We describe recent approaches that improve our understanding of the basic physiology underlying memory and cognition, and their application toward promoting human health.
离子型谷氨酸受体的正向变构调节剂已成为治疗认知障碍、神经退行性变以及诸如重度抑郁症等精神疾病的靶点。研发一类新型药物来治疗难治性心理健康问题的可能性促使研究人员加倍努力，以开发出一种安全、有效的记忆和认知障碍治疗方法。再加上出现的更强大的研究方法，包括更精密的高通量筛选、更高分辨率的结构生物学技术以及对药代动力学更有针对性的评估，AMPA受体正向调节剂的开发前景广阔。我们描述了一些最新方法，这些方法增进了我们对记忆和认知基础基本生理学的理解，以及它们在促进人类健康方面的应用。
